Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Vertex Pharma target raised to $129 at Stifel (89.67)Stifel raises their VRTX tgt to $129 from $100, reiterates Buy. Firm notes that Vertex announced very impressive P3 results for VX-661/Kalydeco in both the F508del homozygous and residual function patient populations. Importantly, FEV1 improvements in the F508del homozygous population of 4% were better than both Street expectations (~3%) and historical Orkambi (2.8%), while bronchoconstriction was a non-issue. This clearly improves the risk/benefit equation for VX-661/Kalydeco over Orkambi and should allow the new combination to improve upon Orkambi' s relatively low penetration/adherence/persistence rates, as well as capture some prior Orkambi patient discontinuations. Moreover, since VX-661/Kalydeco serves as the backbone for the triple combo, they expect optimism to carry Vertex shares higher into 2H17 when they expect to see P2 results from multiple triple combos.</td> </tr></table>"